Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

onClick="var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='93665764';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.aezsinc.com">www.aezsinc.com. A replay will be available on the Company's website for 30 days following the live event.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 10 ,Anesiva, Inc. (Nasdaq: ANSV ) today ... Drug Application (sNDA) with the U.S. Food and ... to treat the pain,associated with peripheral IV insertions ... powder intradermal,injection system is already approved by the ...
... based on data previously reported, communicated in late 2007 ... ... 7 Ortho Biotech Products, L.P.,today modified prescribing information for PROCRIT(R) (Epoetin ... for all drugs within the erythropoiesis-stimulating agent,(ESA) class., Modifications to the ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today announced ... Day event on Thursday, March 13, 2008 from 8:30am,to ... the Grand Hyatt,Hotel in New York, New York., ... look at,the Company,s global operations, business segments, supply chain ...
Cached Biology Technology:Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 2Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 3Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7West to Host Investor Day 2
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces it ... Robbins for the 2015 International CES debut of the ... will be at the NXT-ID booth January 6th and ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... and sea slug expert at the California Academy of ... by the Encyclopedia of Life (EOL). These early-career ... their biodiversity research with colleagues and the general public. ... international collaboration that aims to provide freely accessible information ...
... , MOUNTAIN VIEW, CA January 11, 2011 23andMe ... to be the 10 most interesting and significant genetic findings ... the role of genetics in personal health and human development. ... at a phenomenal rate," stated Anne Wojcicki, co-founder and CEO ...
... cafeteria lines to their menu of tools to help ... U.S. Department of Agriculture recently awarded $40,000 from the ... Conklin, associate professor, hospitality management; and Lisa Bailey-Davis, senior ... project will use economic concepts to study the effect ...
Cached Biology News:Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow 2Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow 323andMe presents top 10 most interesting genetic findings of 2010 223andMe presents top 10 most interesting genetic findings of 2010 323andMe presents top 10 most interesting genetic findings of 2010 423andMe presents top 10 most interesting genetic findings of 2010 523andMe presents top 10 most interesting genetic findings of 2010 623andMe presents top 10 most interesting genetic findings of 2010 723andMe presents top 10 most interesting genetic findings of 2010 823andMe presents top 10 most interesting genetic findings of 2010 923andMe presents top 10 most interesting genetic findings of 2010 1023andMe presents top 10 most interesting genetic findings of 2010 1123andMe presents top 10 most interesting genetic findings of 2010 1223andMe presents top 10 most interesting genetic findings of 2010 1323andMe presents top 10 most interesting genetic findings of 2010 1423andMe presents top 10 most interesting genetic findings of 2010 1523andMe presents top 10 most interesting genetic findings of 2010 1623andMe presents top 10 most interesting genetic findings of 2010 1723andMe presents top 10 most interesting genetic findings of 2010 18Quick school cafeteria lines could lead to healthier food choices 2
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: